Biomea Fusion, Inc. Total Assets
Biomea Fusion, Inc. (BMEA) had Total Assets of $36.87 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-05
- 2026-06-30: Assets $36.87M.
- 2026-03-31: Assets $46.38M.
- 2025-12-31: Assets $58.57M.
- 2025-09-30: Assets $55.19M.
| Period end | Assets |
|---|---|
| 2026-06-30 | $36.87M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $46.38M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $58.57M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $55.19M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $73.16M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $55.05M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $79.94M 10-K · filed 2026-03-24 |
| 2024-09-30 | $110.42M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $136.16M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $168.49M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $199.93M 10-K · filed 2025-03-31 |
| 2023-09-30 | $225.09M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $248.67M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $112.64M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $129.31M 10-K · filed 2024-03-28 |
| 2022-09-30 | $145.05M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $161.74M 10-Q · filed 2022-08-01 |
| 2022-03-31 | $174.86M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $185.71M 10-K · filed 2023-03-28 |
| 2021-09-30 | $199.40M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $209.53M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $59.88M 10-Q · filed 2021-05-27 |
| 2020-12-31 | $62.53M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |